Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (Weighted Average) (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $26.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3.91% to $26.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.9 million through Dec 2025, up 3.91% year-over-year, with the annual reading at $26.9 million for FY2025, 3.91% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $26.9 million in Q4 2025 for Eton Pharmaceuticals, roughly flat from $26.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $26.9 billion in Q2 2025 to a low of $25719.0 in Q3 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $1.4 billion across 5 years, with a median of $25.2 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 99.9% in 2023 and later soared 38756025.68% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $25.2 million in 2021, then fell by 0.24% to $25.1 million in 2022, then increased by 1.99% to $25.6 million in 2023, then grew by 0.97% to $25.9 million in 2024, then grew by 3.91% to $26.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ETON at $26.9 million in Q4 2025, $26.9 million in Q3 2025, and $26.9 billion in Q2 2025.